Antibe Therapeutics Inc.
ATE
Rangering i aksjer
#31900
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Aksjekurs
$0.21483059
Sist synkronisert: 2024-05-07
Markedsverdi
$11.13M
Endring (1 dag)
0.34%
Endring (1 år)
-0.36%
Land
CA
Handel Antibe Therapeutics Inc. (ATE)
Kategori
Healthcare
Utbytteavkastning for Antibe Therapeutics Inc. (ATE)
Antibe Therapeutics Inc. (aksjesymbol: ATE) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Antibe Therapeutics Inc. (ATE) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
| År | Utbytteavkastning | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
| Selskap | Utbytteavkastning | Land |
|---|---|---|
| 2.45% |
US
|
|
| 3.69% |
IE
|
|
| 1.25% |
US
|
|
| 0.00% |
US
|
|
| 0.00% |
DE
|
